Today, the Nanolek executives “have landed” just for one day at the St. Petersburg International Economic Forum - the main business event in Russia, an economic forum held in St. Petersburg. The forum was kicked off with an important event for the pharmaceutical industry - the ceremony of signing of the declaration of the Association of Pharmaceutical Manufacturers AFPEAES, of which Nanolek is a member as well. The declaration on a unified policy in the field of development, production, quality control and monitoring of safety of medicines by the AFPEAES member companies was signed by the CEOs of 9 domestic full-cycle pharmaceutical companies, including by Vladimir Khristenko, President of Nanolek.

The primary purpose of the document is to improve the confidence of patients and doctors in the quality of Russian medicines. Manufacturing companies overcommit to promote the implementation of a patient-centered approach in the healthcare system at all stages of the drug life cycle. The signatories of the declaration also undertake to implement and promote an ethical collaboration between domestic pharmaceutical manufacturers, medical and patient communities, and to improve monitoring facilities for better effectiveness and safety of drugs and medical technologies.

“Today, we have laid the groundwork for establishing an additional mechanism of how to respond to reports of adverse reactions to drugs fr om companies that have signed the declaration,” said Stanislav Naumov, Chairman of the AFPEAES Management Board.

Later that day, Vladimir Khristenko delivered a speech during a preventive immunization panel discussion at the “Drug Safety” forum, wh ere he confirmed the company’s intention to launch the production of CoviVac vaccines (developed by the Chumakov Research Institute) - up to 5 million doses of this COVID-19 vaccine are expected to be produced from the end of summer till the end of 2021.